- Home
- ELBM vs IMUX Comparison
ELBM vs IMUX Comparison
Compare ELBM & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELBM | IMUX |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | Canada | United States |
| Employees | N/A | 66 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.9M | 75.2M |
| IPO Year | 2022 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ELBM | IMUX |
|---|---|---|
| Price | $0.73 | $1.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $2.15 | ★ $4.25 |
| AVG Volume (30 Days) | 728.4K | ★ 4.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $0.51 |
| 52 Week High | $8.70 | $1.35 |
Technical Indicators
Market Signals| Indicator | ELBM | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 34.93 | 76.19 |
| Support Level | N/A | $0.61 |
| Resistance Level | $1.29 | N/A |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 23.36 | 95.79 |
Price Performance
Historical ComparisonAbout ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.